Menu FI EN SV RU Back The cooperation between the University of Eastern Finland and Ferring Ventures SA in gene and cell therapy research continues The University of Eastern Finland has signed a new research cooperation agreement with Ferring Ventures SA. The cooperation agreement on gene and cell therapy research will facilitate the development of the production of new gene therapy vectors. Both parties have a long-term knowledge base in the development of gene therapy drug candidates, and the collaboration that has continued since the beginning of the 21st century has led, among other things, to several patient trials with various gene therapy drugs. Ferring Ventures SA is a company owned by the Kuopio Center for Gene and Cell Therapy (KCT) Oy and FinVector Oy located in Kuopio. Research collaboration with the University of Eastern Finland is strongly related to the activities of the National Viral Vector Laboratory at the AI Virtanen Institute in the Faculty of Health Sciences. Scientific co-operation contributes to the goals of both parties, as new research findings made with the help of the university's strong research infrastructure can be quickly taken forward as business co-operation, if necessary. According to Professor Jussi Pihlajamäki , Dean of the Faculty of Health Sciences at the University of Eastern Finland, over the years business cooperation has also enabled the development of gene therapy manufacturing methods at the university and strengthened the university's profile and competitiveness in EU and ERDF funding applications. - Ferring Ventures values long-term cooperation with the University of Eastern Finland. Cooperation with KCT, FinVector Oy and the AI Virtanen Institute of the University of Eastern Finland will continue in gene and cell therapy research and the development of manufacturing methods in the coming years, said Jean-Frederic Paulsen, Chairman of the Board of Ferring Ventures SA, at the signing ceremony in Kuopio. A.I. Virtanen -instituutti (AIVI) on tutkimuslaitos, joka vastaa väestön ikääntymisen ja muuttuneiden elintapojen tuomiin globaaleihin terveydellisiin haasteisiin keskittymällä sydän- ja verisuonisairauksien sekä aivosairauksien tutkimukseen. Ferring Ventures on sijoitus- sekä kehitysomistajayhtiö, joka tukee uraauurtavien innovatiivisten teknologioiden tutkimusta, kehitystä, tuotantoa ja kaupallistamista geeni- ja soluterapioiden alalla. Kuopio Center for Gene and Cell Therapy (KCT) Oy tekee laadukasta perus- ja translaatiotutkimusta edistyneiden geeni- ja soluterapioiden kehittämiseksi. www.kct.fi FinVector Oy is the world's leading cGMP developer and manufacturer of virus-based gene therapy products. FinVector has built a wide range of gene therapy products and manufacturing technologies from state-of-the-art fully licensed GMP production facilities in Kuopio. FinVector is licensed by FIMEA / EMA to manufacture gene therapy products for clinical and commercial deliveries. www.finvector.com Bulletin of the University of Eastern Finland 11/24/2021 News archive Privacy Statement Accessibility statement Knowledge of the service ELECTRONIC SERVICES Appointments and your health information in OmaKYS - wherever you are. Go to MyKYS CONTACT Address: PO Box 100, 70029 KYS Telephone exchange: 017 173 311 On call: 116 117 Emergency number: 112 Blogs